Intellia Therapeutics (NTLA) Trading Up -6.4%

Shares of Intellia Therapeutics Inc (NASDAQ:NTLA) were up 6.4% during mid-day trading on Thursday . The company traded as high as $26.06 and last traded at $24.02. Approximately 326,619 shares were traded during trading, a decline of 67% from the average daily volume of 975,602 shares. The stock had previously closed at $25.65.

A number of analysts have recently issued reports on NTLA shares. Jefferies Group set a $42.00 target price on shares of Intellia Therapeutics and gave the company a “buy” rating in a research note on Tuesday, October 31st. Leerink Swann boosted their target price on shares of Intellia Therapeutics from $29.00 to $37.00 and gave the company an “outperform” rating in a research note on Tuesday, October 31st. They noted that the move was a valuation call. Barclays reissued a “buy” rating on shares of Intellia Therapeutics in a research note on Sunday, November 5th. Oppenheimer reissued a “hold” rating on shares of Intellia Therapeutics in a research note on Tuesday, December 12th. Finally, ValuEngine lowered shares of Intellia Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, November 15th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $30.17.

In related news, CEO Nessan Bermingham sold 111,500 shares of Intellia Therapeutics stock in a transaction dated Wednesday, December 6th. The stock was sold at an average price of $20.34, for a total value of $2,267,910.00. Following the completion of the sale, the chief executive officer now directly owns 696,000 shares in the company, valued at $14,156,640. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Institutes For Biomed Novartis sold 1,523,000 shares of Intellia Therapeutics stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $18.30, for a total value of $27,870,900.00. The disclosure for this sale can be found here. Insiders sold 2,521,928 shares of company stock valued at $51,883,434 over the last 90 days. 12.80% of the stock is currently owned by corporate insiders.

Several hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its holdings in shares of Intellia Therapeutics by 1.9% in the fourth quarter. BlackRock Inc. now owns 1,710,947 shares of the company’s stock valued at $32,885,000 after acquiring an additional 31,662 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Intellia Therapeutics by 10.2% in the second quarter. Vanguard Group Inc. now owns 997,288 shares of the company’s stock valued at $15,957,000 after acquiring an additional 92,580 shares in the last quarter. GMT Capital Corp bought a new stake in shares of Intellia Therapeutics in the third quarter valued at about $8,214,000. Granahan Investment Management Inc. MA raised its holdings in Intellia Therapeutics by 7.0% in the third quarter. Granahan Investment Management Inc. MA now owns 286,144 shares of the company’s stock worth $7,111,000 after purchasing an additional 18,784 shares in the last quarter. Finally, Artal Group S.A. raised its holdings in Intellia Therapeutics by 42.9% in the fourth quarter. Artal Group S.A. now owns 250,000 shares of the company’s stock worth $4,805,000 after purchasing an additional 75,000 shares in the last quarter. Hedge funds and other institutional investors own 48.12% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Intellia Therapeutics (NTLA) Trading Up -6.4%” was posted by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.com-unik.info/2018/02/10/intellia-therapeutics-ntla-trading-up-6-4.html.

About Intellia Therapeutics

Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit